Limits...
Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents: profile report.

Keating GM - Drugs R D (2012)

View Article: PubMed Central - PubMed

Affiliation: Adis, Auckland, New Zealand. demail@springer.com

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

A patch that delivers methylphenidate transdermally (methylphenidate transdermal system; Daytrana®) has been developed for the treatment of ADHD... The patch comprises a backing layer, an adhesive formulation that incorporates methylphenidate and uses DOT Matrix™ technology, and a protective liner, which is removed prior to application... The features and properties of methylphenidate transdermal system (including available patch sizes and the nominal methylphenidate dose delivered by each patch size) are shown in table I... Once applied to the skin, methylphenidate transdermal system releases methylphenidate continuously... A potential advantage of this patch technology is that it allows the duration of the effect to be tailored to the individual by varying the duration of the application (‘wear time’)... Adolescents aged 13–17 years with ADHD were randomized to receive methylphenidate transdermal system or placebo transdermal system in a double-blind, multicenter, 7-week trial (core trial)... According to the results of the core trial, methylphenidate transdermal system 10–30 mg was effective in adolescents aged 13–17 years with ADHD... The mean ADHD-Rating Scale-IV (ADHD-RS-IV) total score (primary endpoint) decreased to a significantly (p < 0.001) greater extent in adolescents receiving methylphenidate transdermal system (n = 143) than in those receiving placebo transdermal system (n = 72), with a least squares mean between-group difference of -9.96 (95% CI -13.39, -6.53)... The mean ADHD-RS-IV total score at study end was 17.7 in methylphenidate transdermal system recipients and 27.7 in placebo transdermal system recipients; the mean baseline scores were 36.4 and 36.6 in the corresponding treatment groups... In the extension study, methylphenidate transdermal system recipients experienced a significant (p < 0.001) reduction from the start of the core trial in the mean ADHD-RS-IV total score of 23.0... In the core trial, the most frequently reported treatment-emergent adverse events (occurring in ≥5% of methylphenidate transdermal system recipients and in numerically more methylphenidate transdermal system than placebo transdermal system recipients) included decreased appetite, irritability, upper respiratory tract infection, nausea, insomnia, dizziness, and decreased weight.

Show MeSH
Features and properties of methylphenidate transdermal system (Daytrana®)[1]
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585903&req=5

Tab1: Features and properties of methylphenidate transdermal system (Daytrana®)[1]

Mentions: A patch that delivers methylphenidate transdermally (methylphenidate transdermal system; Daytrana®) has been developed for the treatment of ADHD. The patch comprises a backing layer, an adhesive formulation that incorporates methylphenidate and uses DOT Matrix™ technology, and a protective liner, which is removed prior to application.[5] The features and properties of methylphenidate transdermal system (including available patch sizes and the nominal methylphenidate dose delivered by each patch size) are shown in table I. Once applied to the skin, methylphenidate transdermal system releases methylphenidate continuously. A potential advantage of this patch technology is that it allows the duration of the effect to be tailored to the individual by varying the duration of the application (‘wear time’).[6]


Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents: profile report.

Keating GM - Drugs R D (2012)

Features and properties of methylphenidate transdermal system (Daytrana®)[1]
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585903&req=5

Tab1: Features and properties of methylphenidate transdermal system (Daytrana®)[1]
Mentions: A patch that delivers methylphenidate transdermally (methylphenidate transdermal system; Daytrana®) has been developed for the treatment of ADHD. The patch comprises a backing layer, an adhesive formulation that incorporates methylphenidate and uses DOT Matrix™ technology, and a protective liner, which is removed prior to application.[5] The features and properties of methylphenidate transdermal system (including available patch sizes and the nominal methylphenidate dose delivered by each patch size) are shown in table I. Once applied to the skin, methylphenidate transdermal system releases methylphenidate continuously. A potential advantage of this patch technology is that it allows the duration of the effect to be tailored to the individual by varying the duration of the application (‘wear time’).[6]

View Article: PubMed Central - PubMed

Affiliation: Adis, Auckland, New Zealand. demail@springer.com

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

A patch that delivers methylphenidate transdermally (methylphenidate transdermal system; Daytrana®) has been developed for the treatment of ADHD... The patch comprises a backing layer, an adhesive formulation that incorporates methylphenidate and uses DOT Matrix™ technology, and a protective liner, which is removed prior to application... The features and properties of methylphenidate transdermal system (including available patch sizes and the nominal methylphenidate dose delivered by each patch size) are shown in table I... Once applied to the skin, methylphenidate transdermal system releases methylphenidate continuously... A potential advantage of this patch technology is that it allows the duration of the effect to be tailored to the individual by varying the duration of the application (‘wear time’)... Adolescents aged 13–17 years with ADHD were randomized to receive methylphenidate transdermal system or placebo transdermal system in a double-blind, multicenter, 7-week trial (core trial)... According to the results of the core trial, methylphenidate transdermal system 10–30 mg was effective in adolescents aged 13–17 years with ADHD... The mean ADHD-Rating Scale-IV (ADHD-RS-IV) total score (primary endpoint) decreased to a significantly (p < 0.001) greater extent in adolescents receiving methylphenidate transdermal system (n = 143) than in those receiving placebo transdermal system (n = 72), with a least squares mean between-group difference of -9.96 (95% CI -13.39, -6.53)... The mean ADHD-RS-IV total score at study end was 17.7 in methylphenidate transdermal system recipients and 27.7 in placebo transdermal system recipients; the mean baseline scores were 36.4 and 36.6 in the corresponding treatment groups... In the extension study, methylphenidate transdermal system recipients experienced a significant (p < 0.001) reduction from the start of the core trial in the mean ADHD-RS-IV total score of 23.0... In the core trial, the most frequently reported treatment-emergent adverse events (occurring in ≥5% of methylphenidate transdermal system recipients and in numerically more methylphenidate transdermal system than placebo transdermal system recipients) included decreased appetite, irritability, upper respiratory tract infection, nausea, insomnia, dizziness, and decreased weight.

Show MeSH